NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is an emerging biotechnology company engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy. The acquisition of PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.
NeoStem announced that several of its representatives have been invited to present at the Seventh International Conference on Cell Therapy for Cardiovascular Disease held from January 25-27, 2012 in New York City. The invited include NeoStem’s Chief Medical Officer, the lead investigator for its PreSERVE Phase 2 clinical trial for AMR-001 for preservation of heart function in post acute myocardial infarction patients, and the President of Progenitor Cell Therapy, LLC, a NeoStem subsidiary.
The Cardiovascular Research Foundation is organizing the conference, which will be held at the Myrna L. Daniels Auditorium in the Vivien and Seymour Milstein Family Heart Center at NYPH/Columbia University Medical Center.
The program “will be dedicated to the evolving field of cell-based therapies being developed for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.” The conference this year “will focus on preclinical and clinical studies on the path to commercialization, highlighting the status of molecular, cell, and tissue products in addition to delivery systems. Leaders from the international community will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.”
NeoStem will present as follows:
- At 4:30 PM on Wednesday, January 25, Andrew L. Pecora, MD, FACP, Chief Medical Officer of NeoStem, will speak on an industry session entitled "Focus on Acute Injury Technologies."
- At 9:20 AM on Thursday, January 26, Arshed A. Quyyumi, MD, FRCP, FACC, principal investigator of the PreSERVE AMI Phase 2 trial and Professor of Medicine and Cardiology at Emory University, will speak on a panel entitled "Early and Next Phase Studies" within a session entitled "Acute Injury: STEMI and NSTEMI".
- From 7:30 to 8:30 AM on Friday, January 27, Robert A. Preti, PhD, President of Progenitor Cell Therapy will speak as part of Industry Session III entitled "Focus on Procedure, Systems Management, and Advanced Technologies."
Dr. Pecora, CMO of NeoStem, commented,
"As a presenter at the first industry session, I look forward to informing industry leaders about the PreSERVE Phase 2 clinical trial for AMI which is now open for enrollment and may provide data readout 18 months from the first patient enrollment, as well as discussing the recent patent issued to use the Amorcyte technology beyond cardiovascular disease."
Chairman and CEO of NeoStem Dr. Robin L. Smith added,
"This conference represents validation that the development of cell therapies for diseases outside of bone marrow transplantation is progressing as represented by their current clinical data. Our acquisition of Amorcyte last year has positioned NeoStem to be a leader in the cell therapy cardiovascular space. We are excited to be a part of the developing science represented by this important conference and share our expertise represented by the progress with Amorcyte and our capabilities to assist the field with the manufacturing services of PCT."